Background {#Sec1}
==========

Visceral leishmaniasis (VL) and HIV co-infection is common in tropical areas and can occur in southern European countries \[[@CR1]\]. Concerning the WHO European Region, the estimated annual incidence of VL/HIV co-infection is around 1100--1900 cases/year \[[@CR2]\]. The *Leishmania*-HIV interplay at the cellular and molecular level appears to affect the course of infection for both pathogens \[[@CR3]\] as VL hampers the immunological competence of HIV-positive patients, while HIV-infected patients with VL exhibit reduced anti-leishmanial drug response, frequent relapses and higher mortality rates than HIV-negative individuals \[[@CR1], [@CR2]\]. A combination anti-leishmanial therapy might be considered in HIV/VL co-infection, especially for HIV patients with refractory cases of VL \[[@CR4], [@CR5]\]. Nevertheless, a valuable multidrug therapy and optimal treatment duration have yet to be established.

Case description {#Sec2}
================

We report on two patients with *Leishmania infantum*-induced VL and HIV-1 co-infection who received an extended course of a salvage therapy (anti-leishmanial combination treatment, cAnti-Leish) in addition to antiretroviral therapy (ART). The rationale behind multidrug therapy against *Leishmania* was to increase drug activity with compounds targeting different pathways of the parasite metabolism, ultimately preventing the emergence of drug resistance. Drugs with distinct activity against *Leishmania* were used, including those targeting ergosterol biosynthesis (liposomal amphotericin B \[L-amB\] and fluconazole) and cell membrane integrity (L-amB), modulating surface signaling pathways (miltefosine) interfering with the purine salvage pathway (allopurinol) and hindering DNA synthesis at mitochondrial level (pentamidine) \[[@CR6], [@CR7]\]. Furthermore, HIV-1 protease inhibitors (PI) were employed as adjunctive anti-leishmanial therapy for HIV-associated VL \[[@CR8]\]. In fact, in vitro \[[@CR9]\] and in vivo \[[@CR10]\] evidence suggests that high dose PI hamper *Leishmania* replication and exhibit synergistic effect with L-amB and miltefosine \[[@CR10]\].

Our regimen resulted in good control of VL and HIV-1 infection in both patients, whereas previously administered conventional monotherapy with L-amB (dosage regimen of 4 mg/kg on days 1--5, 10, 17, 24, 31 and 38, for a total dose of 40 mg/kg) followed by secondary prophylaxis (3 mg/kg every 4 weeks) did not prevent multiple VL relapses. The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patients included in the study.

Case 1 was a 55-year-old man who presented at the Unit of Infectious Diseases, Forlì Hospital (northeastern Italy) with a 4-year history of HIV infection and a 2-year history of disseminated cutaneous leishmaniasis. Despite being under secondary prophylaxis with L-amB, severe gastroenterological disease caused by *Leishmania* was discovered. Case 2 was a 50-year old HIV-positive man who presented with a 6-year history of HIV infection and a 3-year history of disseminated cutaneous leishmaniasis and VL, recalcitrant to therapy with L-amB.

Leishmanial DNA was detected by real-time PCR in the peripheral blood, bone marrow aspirates and skin biopsies of both patients (Fig. [1](#Fig1){ref-type="fig"} and not shown). Additionally, stomach and colon biopsies from Case 1 tested positive for leishmanial DNA. In both cases, bone marrow showed high levels of parasitemia (around 10E6 parasite genomes/mL), while lower levels (around 10E2--10E3 parasite genomes/mL) were detected in peripheral blood (Fig. [1](#Fig1){ref-type="fig"}). Patients exhibited a CD4+ count of 225 cells/μL and 170 cells/μL before cAnti-Leish, Case 1 and Case 2, respectively. The nadir CD4 cell count was 120 cells/μL and 143 cells/μL, Case 1 and Case 2, respectively.Fig. 1Time course of parasitological and immunological parameters upon combined anti-leishmanial treatment in Case 1 (**a**) and Case 2 (**b**). Parasitemia (red circles) was measured by quantitative real-time PCR (qPCR) before and after anti-leishmanial combination (cAnti-Leish) treatment. Also shown is the CD4+ cell count in peripheral blood (empty squares; normal range: 500--1500 cells/μL). HIV RNA was \< 40 copies/mL in Case 1 and Case 2 throughout the study as tested by the Veris DxN HIV-1 assay (Beckman Coulter, Brea, CA USA). Leishmanial DNA was detected in peripheral blood by two distinct real-time (RT) PCR assays, amplifying segments of the small-subunit ribosomal RNA gene and the kinetoplast DNA (kDNA) \[[@CR15]\]. Samples testing positive for parasitic DNA were then quantified by RT-PCR for the single copy polymerase gene (*pol*) of *Leishmania* \[[@CR16]\]. The detection limit was 0.00005 parasite/reaction for kDNA RT-PCR and 1 parasite/reaction for *pol* RT-PCR. *Leishmania* typing was performed by hsp70 PCR \[[@CR17]\] and *L. infantum* was identified in both patients. ▲: Parasitemia was quantified in bone marrow aspirates within one week before cAnti-Leish onset

High and intermittent doses of L-amB in 5% dextrose i.v. infusion over 4 h (4 mg/kg/day on days 1--5, 10, 17, 24, 32 and 38) were administered for VL treatment \[[@CR1], [@CR4]\]. The patients also received concomitant miltefosine (50 mg three times/day for 28 days), allopurinol (300 mg four times daily for 15 days) and de-escalating doses of fluconazole (from 600 to 400 mg/day for 28 days). Since PI can also be considered an adjunctive anti-leishmanial therapy, ART was modified by adding a boosted PI treatment, including darunavir (800 mg/day) and ritonavir (100 mg/day) in Case 1 and atazanavir (300 mg/day) and ritonavir (100 mg/day) in Case 2, respectively, while the backbone therapy included lamivudine 300 mg/day and tenofovir disoproxil fumarate (245 mg/day) in both patients. Once remission was achieved, including resolution of fever, remarkable improvement of the patient's general condition, regression of splenomegaly and amelioration of laboratory parameters, a maintenance treatment was instituted for 12 weeks with L-AmB (2--3 mg/kg every 3 weeks), miltefosine (50 mg three times weekly), allopurinol (300 mg twice daily), fluconazole (400 mg/day) and pentamidine aerosol (300 mg twice a month for the first 2 months, then once a month for 6 months). One week after cAnti-Leish onset, there was a significant decline in peripheral blood parasitemia (Fig. [1](#Fig1){ref-type="fig"}); we observed a good correlation between clinical outcome and blood parasite burden. To consolidate activity against potentially residual parasites, a second cycle of the initial and maintenance therapy was given to both patients (Case 1 only received 2 mg/kg L-Amb in the second cycle). Secondary prophylaxis with L-Amb (2--3 mg/kg every 3--4 weeks) was subsequently administered. Parasite genomes were not detectable over time up to the last follow-up visit (Week 57 and Week 78 for Case 1 and Case 2, respectively). CD4+ lymphocyte counts fluctuated over time, but were generally higher than counts detected at treatment onset, which likely contributed to protection against VL relapse.

Discussion and conclusions {#Sec3}
==========================

It has been suggested that combined drug regimens are the best option for VL/HIV co-infected patients by increasing drug efficacy, reducing toxicity and hampering the emergence of resistance \[[@CR4], [@CR5]\]. So far, the best combination therapy appears to be L-amB plus miltefosine due to the observed synergism between the two compounds in vitro and in animal models \[[@CR11]\]. Furthermore, a combination regimen consisting of L-amB and miltefosine was employed in VL/HIV co-infected patients in a pilot study performed by Médecin Sans Frontières in Ethiopia \[[@CR12]\] as well as in 120 VL/HIV co-infected patients in India \[[@CR13]\], showing encouraging results.

Here, the employment of L-amB and miltefosine was associated to other drugs with anti-leishmanial effects, including fluconazole, allopurinol and pentamidine. Results achieved with cAnti-Leish were promising, but are based on only two patients. Thus, future investigation is necessary to confirm the efficacy of this salvage therapy. Furthermore, the potentially synergistic role of cAnti-Leish and a PI-based ART regimen in sustaining the immunological response and control of VL should be further explored as recent evidence suggests that both CD4+ count and circulating *Leishmania* DNA contribute to prognosis in HIV/VL co-infection \[[@CR14]\].
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